Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia
NCT04897217 · Wake Forest University Health Sciences · PHASE3 · withdrawn · last registry update 2023-07-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI decision” | – | Registry record, Wake Forest University Health Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PGR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-06-25Results posted on the registry: Myovant Sciences GmbH, Relugolix + Estradiol/norethindrone acetate (NCT03751124)
- 2024-06-20Also stopped (terminated): Organon and Co, NOMAC-E2 + NETA-EE (NCT01656434)
- 2024-06-03Phase 3 first posted: Main Line Health, 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate (NCT06439524)
- 2024-05-17Also stopped (terminated): Organon and Co, ENG-E2 125 μg/300 μg vaginal ring + LNG-EE 150 μg/30 μg COC (NCT02616146)
- 2024-05-14Results posted on the registry: Medicines360, Levonorgestrel 52 mg intrauterine system (NCT03642210)
- 2024-05-09Results posted on the registry: Myovant Sciences GmbH, Relugolix + Estradiol/norethindrone acetate (NCT03412890)
- 2024-05-06Results posted on the registry: Dr. Hang Wun Raymond Li, Piroxicam 40 mg + Levonorgestrel 1.5mg (NCT03614494)
- 2024-05-01Phase 3 first posted: Leiden University Medical Center, Mifepristone 50 mg (NCT06394999)
- 2024-04-19Results posted on the registry: University of California, San Diego, Progestin Only Contraceptive Pills (NCT04965116)
- 2024-03-15Results posted on the registry: Merck KGaA, Darmstadt, Germany, Cladribine + Placebo (NCT03745144)
- 2024-03-13Results posted on the registry: Boehringer Ingelheim, Microgynon® 30 + BI 409306 (NCT03193307)
- 2024-02-20Results posted on the registry: Planned Parenthood of the St. Louis Region and Southwest Missouri, Ulipristal acetate (NCT01539720)
- 2024-02-16Results posted on the registry: University of Chicago, Mifepristone + Nab-Paclitaxel (NCT02788981)
- 2024-02-06Results posted on the registry: Oregon Health and Science University, UPA-ECx1 + UPA-ECx2 (NCT02859337)
- 2024-02-05Results posted on the registry: FHI 360, a drug against PGR (NCT01721798)
- 2024-02-02Also stopped (terminated): Baylor Research Institute, Norethindrone acetate (NTA) + Placebo (NCT04676061)
- 2023-11-18Phase 3 first posted: Fundación Santiago Dexeus Font, 150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5 + 150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger (NCT06134479)
- 2023-11-18Also stopped (terminated): Children's Hospital Los Angeles, Desogestrel (NCT01500473)
- 2023-10-16Results posted on the registry: Memorial Sloan Kettering Cancer Center, a drug against PGR (NCT02477202)
- 2023-09-28Results posted on the registry: Children's Hospital Los Angeles, Desogestrel (NCT01500473)
- 2023-08-31Phase 3 first posted: Chemo Research, LVDS (NCT06019533)
- 2023-08-04Results posted on the registry: Icahn School of Medicine at Mount Sinai, Danazol (NCT00953771)
- 2023-07-25Also stopped (terminated): Gynuity Health Projects, Mifepristone + 2 doses of misoprostol 800 mcg (NCT05119439)
- 2023-07-20Results posted on the registry: Myovant Sciences GmbH, Relugolix + Estradiol/norethindrone acetate (NCT03654274)
- 2023-06-15Results posted on the registry: Oregon Health and Science University, Levonorgestrel-based emergency contraception 1.5 mg + Levonorgestrel-based emergency contraception 3.0mg (NCT02863445)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision